0       0

AST 2014 - Cutting Edge of Transplantation


TH01b - Where Will New Therapeutics Come From: Academia or Pharma?


Feb 13, 2014 5:10pm ‐ Feb 13, 2014 5:40pm

Description

Since the mortality rates five years after many solid organ transplants are similar to the mortality rates five years after the first diagnosis of many common cancers, new therapeutic strategies for transplant recipients are desperately needed. While academia continues to produce the basic knowledge required to discover and develop more effective, safer and more cost-effective therapeutics, industry and academia must work together to conduct the clinical trials required for regulatory approval of improved therapeutics. Despite the current unmet clinical need for improved therapeutics, there is a gap in needed expertise and new approaches between where basic science ends and where later stages of clinical trial development begin. Solutions to bridge this gap will be proposed suggesting that the answer to the question is that academia, industry as well as new organizations that bridge this gap are all needed for the creation of new therapeutics.

Speaker(s):

  • Randy Morris, MD, FRCP, Stanford University School of Medicine

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-speaker-name image
token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content